Curated News
By: NewsRamp Editorial Staff
November 06, 2025

Datavault AI Licenses Tech to Scilex for $2.5T Biotech Tokenization

View History of this news story on GitHub
Original Source

TLDR

  • Datavault AI grants Scilex exclusive biotech license, creating a $2 trillion market opportunity for non-dilutive funding through asset tokenization.
  • Datavault AI's proprietary technology enables Scilex to build a Biotech Exchange platform for tokenizing, trading, and monetizing genomic data and drug information.
  • This partnership advances biotech innovation by enabling secure data sharing and funding access, potentially accelerating medical breakthroughs and treatments.
  • Datavault AI's deal includes a $10 million upfront payment and up to $2.55 billion in milestones for blockchain-based biotech asset tokenization.

Impact - Why it Matters

This partnership represents a significant convergence of artificial intelligence, blockchain, and biotechnology that could fundamentally transform how medical and scientific data is valued and monetized. For the healthcare industry, it introduces new pathways for biotech companies to access non-dilutive funding while creating more efficient markets for genomic data, diagnostic information, and drug development assets. Patients and researchers could benefit from accelerated innovation as valuable data becomes more accessible and tradable, potentially leading to faster drug discovery and personalized medicine advancements. The $2 trillion market opportunity indicates this technology could reshape financial models across the pharmaceutical sector, creating new revenue streams while addressing longstanding challenges in data sharing and collaboration within the highly regulated biotech industry.

Summary

Datavault AI (NASDAQ: DVLT), a prominent leader in AI-driven blockchain solutions for data monetization and asset tokenization, has entered into a groundbreaking licensing agreement with Scilex Holding Company (NASDAQ: SCLX), granting the biotech firm exclusive worldwide rights to deploy Datavault AI's proprietary technology within the biotech and biopharma sectors. This strategic partnership enables Scilex to develop and operate a sophisticated Biotech Exchange platform that will revolutionize how biotech assets—including genomic data, diagnostic information, and drug development data—are tokenized, traded, and monetized. The deal represents a significant expansion of Datavault AI's technology into the life sciences arena, with the company anticipating this will evolve into a comprehensive Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity while providing companies with access to non-dilutive funding alternatives.

The financial terms of this landmark agreement include a substantial $10 million upfront payment structured across four installments, complemented by potential milestone payments reaching up to $2.55 billion, reflecting the enormous value both companies see in this collaboration. Datavault AI brings to the table its extensive patent portfolio and proven high-performance computing expertise, which has been successfully deployed across multiple industries including sports & entertainment, events & venues, education, fintech, real estate, healthcare, and energy. The company's Information Data Exchange (IDE) technology enables the creation of Digital Twins and facilitates the licensing of name, image, and likeness (NIL) by securely linking physical real-world objects to immutable metadata objects, fostering responsible AI implementation with integrity. This comprehensive technology suite offers AI and Machine Learning automation, third-party integration capabilities, detailed analytics, marketing automation, and advertising monitoring, making it particularly well-suited for the complex requirements of the biotech sector.

For those seeking additional information about this transformative partnership, the full press release is available through the InvestorBrandNetwork's comprehensive coverage of Datavault AI's latest developments. The AINewsWire platform, which specializes in artificial intelligence advancements and serves as part of the Dynamic Brand Portfolio within the InvestorBrandNetwork, provides extensive distribution and communication services for companies operating in the AI space. This licensing agreement represents a significant milestone in the convergence of artificial intelligence, blockchain technology, and biotechnology, potentially setting new standards for how valuable scientific and medical data assets are managed, monetized, and leveraged for innovation across the healthcare and pharmaceutical industries.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Datavault AI Licenses Tech to Scilex for $2.5T Biotech Tokenization

blockchain registration record for this content.